September 11, 2015 9:16am

KTE-C19 is an investigational therapy in which a patient's T cells are genetically engineered to express a chimeric antigen receptor (CAR) designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias. KITE closed at $61.15 and is UP +0.54% or $0.33 in the pre-market. Maintaining BUY


Members only. Please login.